Recombinant lipase(Groupe Mayoly Spindler)

BOCA RATON, FL, USA I November 13, 2024 I Entero Therapeutics, Inc. (Nasdaq: ENTO) (“Entero” or the “Company”), today announced that it has entered into a binding term sheet for a reverse merger transaction (the “Proposed Merger”) with Journey Therapeutics, Inc. (“Journey”), a privately-held, clinical-stage biopharmaceutical company with a next-generation proprietary modular antibody-drug conjugate (ADC)-like, nano-immunoconjugates (NIC) platform. Upon completion of the Proposed Merger, the shareholders of Journey will acquire 99% of the equity of Entero. The combined company is expected to operate under the name Journey Therapeutics, Inc., and will apply for continued trading on The Nasdaq Capital Market. The completion of the Proposed Merger is subject to several conditions, including the negotiation of definitive agreements, the receipt by Entero of at least $5 million of equity financing, the effectiveness of a registration statement to be filed with the Securities and Exchange Commission and the approval of the stockholders of Entero. Following the completion of the Proposed Merger, the new entity would be under the leadership of Henry Ji, Ph.D., Chairman and Chief Executive Officer of Journey Therapeutics. It is contemplated that the combined company will prioritize advancing Journey’s first-in-class, next-gen NIC product candidates targeting gynecological cancers, advanced non-Hodgkin’s lymphoma and other difficult to treat cancers, alongside Entero’s existing clinical assets. These existing assets include a latiglutenase, a pioneering oral biotherapeutic for celiac disease, adrulipase, a recombinant lipase enzyme for cystic fibrosis and chronic pancreatitis, and capeserod, a selective 5HT-4 receptor partial agonist, all of which would continue undergoing clinical development. “The Proposed Merger with Journey Therapeutics presents an exceptional opportunity for Entero, bringing groundbreaking NIC technology and invaluable expertise under the leadership of Dr. Henry Ji,” said James Sapirstein, Chairman and Chief Executive Officer of Entero Therapeutics. “Journey’s innovative, first-in-class therapies hold tremendous potential and, after the proposed merger is completed, we are excited to accelerate the key steps to initiate critical clinical trials. This transaction would position us to make significant strides in the oncology sector, tapping into a multibillion-dollar global market and advancing potentially life-changing therapies for patients.” “Journey looks forward to this proposed merger with Entero Therapeutics, as it allows us to build a publicly traded company that is driven toward advancing Journey’s first-in-class, next-gen nano-immunoconjugates portfolio to rival the advanced antibody-drug conjugates products,” stated Henry Ji, Ph.D., President and Chief Executive Officer of Journey Therapeutics. “This opportunity arises at a momentous stage in Journey’s development, as we prepare for clinical trials of our two leading assets with encouraging initial clinical results.” Journey is a clinical-stage, biopharmaceutical company pioneering advanced cancer therapies that leverage nanotechnology and immunotherapy. Rivalling antibody-drug conjugates (ADC), its NIC platform is designed to target tumors precisely, delivering therapeutic agents directly to cancer cells with minimal impact on surrounding healthy tissue. By combining nanotechnology with immunoconjugates, Journey has developed technology that permits modular antibody-based targeting and tailored chemotherapeutic selection, potentially leading to more effective and less toxic treatment of a variety of cancer types. This innovative approach holds tremendous promise for the future of precision oncology. As described by the inventor, Svetomir N. Markovic, M.D., Ph.D. (Mayo Clinic), the NIC platform seeks to usher the next generation of antibody-drug complex therapeutics to enable simultaneous multi-drug delivery to multiple cancer targets. Early, Phase 1 clinical data with two prototype NICs engineered to treat end-stage metastatic ovarian/endometrial cancer (targeting VEGF) or non-Hodgkin’s lymphoma (targeting CD20) have shown highly encouraging results in clinical efficacy and safety. For more information about Entero Therapeutics, visit www.enterothera.com and connect on X and LinkedIn . Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research. About Entero Therapeutics Entero Therapeutics, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company’s programs address significant unmet needs in GI health and include: latiglutenase, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. For more information visit www.enterothera.com . About Journey Therapeutics Journey Therapeutics, Inc. is a clinical stage biopharmaceutical company developing a portfolio of antibody-coated nanoparticle albumin-bound (“NAB or nab”) paclitaxel (the Nano-immunoconjugates (“NIC”)) for the treatment of various cancers. Invented by Svetomir Markovic, MD, Ph.D. at Mayo Clinic in Rochester, Minnesota, the clinically-validated NIC platform, a next-generation antibody-drug conjugates (“ADC”) rivalling platform, complexes tumor targeting, immune modulating and/or tumor-suppressing monoclonal antibodies and nab-paclitaxel into a pipeline of innovative drug products for unmet medical needs. About Nano-Immunoconjugates (NIC) Therapeutic Platform Invented by Svetomir Markovic, M.D., Ph.D. at Mayo Clinic in Rochester, Minnesota, the clinically-validated NIC platform is a proprietary next-generation antibody-drug conjugate (ADC) rivalling therapeutic technology and offers a number of advantages over existing ADC approaches, including: SOURCE: Entero Therapeutics

Entero Therapeutics announced Wednesday it has signed a proposed reverse merger agreement with Journey Therapeutics, a developer of next-generation antibody-drug conjugate (ADC)-rivalling cancer treatments.“This opportunity arises at a momentous stage in Journey’s development, as we prepare for clinical trials of our two leading assets with encouraging initial clinical results,” remarked Journey CEO Henry Ji. The merged entity will operate under the name Journey Therapeutics, with Ji taking the helm.The new company will focus on advancing candidates designed using Journey’s modular nano-immunoconjugates (NIC) platform to treat gynaecological cancers and advanced non-Hodgkin’s lymphoma, while continuing to develop Entero’s pipeline of gastrointestinal (GI) therapies.Under the binding term sheet agreement signed by the parties, Journey’s existing stockholders will control 99% of the merged entity, and seek continued listing on the NASDAQ. While the precise terms of the deal remain undisclosed, the proposed merger remains subject to certain conditions, including a minimum $5 million equity investment, approval from Entero shareholders, and regulatory clearances. Journey’s NICs assets — designed as advanced alternatives to ADCs — use a nanoparticle albumin-bound Abraxane (paclitaxel) backbone to target tumours precisely, minimising harm to healthy tissue and enabling tailored drug delivery. A brainchild of Mayo Clinic’s Svetomir Markovic, the platform combines nanotechnology with immunotherapy, supporting simultaneous multi-drug delivery for diverse cancer targets. Early-stage clinical data of NIC candidates have shown promising efficacy and safety in treating metastatic ovarian cancer and non-Hodgkin’s lymphoma.On the other hand, Entero Therapeutics, earlier known as First Wave BioPharma, is developing targeted, non-systemic therapies for GI diseases. Its pipeline includes latiglutenase, a potential first-in-class oral treatment for ceoliac disease; capeserod, a selective 5-HT4 agonist for gastroparesis; and adrulipase, a recombinant enzyme to aid fat digestion in cystic fibrosis and chronic pancreatitis. With the aim to move latiglutenase to late-stage testing next year, the biotech raised $1.9 million and consolidated operations in August.“This transaction would position us to make significant strides in the oncology sector..advancing potentially life-changing therapies for patients,” remarked James Sapirstein, chief executive of Entero.There has been a recent flurry of reverse merger deals in the biotech space, including Aerovate Therapeutics merging with Paragon Therapeutics’ spinout Jade Biosciences, and Relief Therapeutics finalising its merger with Renexxion.